Literature DB >> 2854771

SV40-transformed human fibroblasts exhibit a characteristic chromosomal pattern.

F Hoffschir1, M Ricoul, B Dutrillaux.   

Abstract

A karyotype study of seven SV40-transformed human fibroblast cell lines was performed using R-banding. Although large variations existed from line to line and, to a lesser degree, from cell to cell in a given line, many common features were found. The most characteristic were chromosome imbalances. Some of the chromosomes or chromosome segments present in excess were, in decreasing order of frequency, the early replicating X, 12q, 3q, 12p, 19, 1p, and 6p. Losses of other chromosomes and chromosome segments were also frequent and involved 11p, 2p, 6q, 10p, 18, 4q, 8p, 4p, 10q, and 16. These imbalances seemed to correlate with metabolic characteristics, previously described, such as low activities of catalase (11p), superoxide dismutase 2 (6q), and acid phosphatase (2p, 11p) and a high ratio of lactate dehydrogenase B (LDHB, 12p) activity to LDHA (11p) activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854771     DOI: 10.1159/000132674

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  3 in total

1.  Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association.

Authors:  I Vorechovsky; J Litzman; J Lokaj; P Hausner; T Poch
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Karyotype alteration generates the neoplastic phenotypes of SV40-infected human and rodent cells.

Authors:  Mathew Bloomfield; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2015-10-22       Impact factor: 2.009

3.  SV40 Transfected Human Anterior Cruciate Ligament Derived Ligamentocytes-Suitable as a Human in Vitro Model for Ligament Reconstruction?

Authors:  Gundula Schulze-Tanzil; Philipp Arnold; Clemens Gögele; Judith Hahn; Annette Breier; Michael Meyer; Benjamin Kohl; Michaela Schröpfer; Silke Schwarz
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.